BIOCRYST PHARMACEUTICALS, INC. (BCRX)

9.82USD -0.51% (-0.05)

Over 1M: +9.4%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

9 10
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 159.4M Q3 '25 — Operating Cash Flow: 41.6M Q3 '25 — Free Cash Flow: 40.3M Q3 '25 — Net Income: 12.9M Q4 '25 — Revenue: 406.6M Q4 '25 — Operating Cash Flow: 292M Q4 '25 — Free Cash Flow: 291.2M Q4 '25 — Net Income: 245.8M Q1 '26 — Revenue: 156.4M Q1 '26 — Operating Cash Flow: -61.8M Q1 '26 — Free Cash Flow: -62.2M Q1 '26 — Net Income: -721.8M Q2 '26 — Revenue: 218.2M Q2 '26 — Operating Cash Flow: 104.3M Q2 '26 — Free Cash Flow: 104.1M Q2 '26 — Net Income: 78.4M -500M -250M 0 250M 500M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 62 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

4.1
OE margin 31.9%
Oper. margin -33.3%
Accruals -136.4%
FCF margin 39.7%
Gross margin 97.8%
OCF margin 40.0%
EBITDA margin -33.2%
Profit margin -40.9%
ROA -69.0%
ROCE -89.7%
OCF / EBIT —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

10.0
EV/OE 8.5×
EV/Sales 2.7×
FCF yield 14.9%
P/C 7.1×
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

4.4
RPO / sales 0.013×
RPO growth —
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

3.4
ND/EBITDA -0.018
Debt payback 0.12 yr
Quick ratio 2.3×
Cash / Debt 0.89×
F-score 7.0 pts
Cash runway —
Debt / Eq —
Equity / Assets —
Net debt / Eq —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

7.2
Sales/sh Y/Y +59.5%
Sales CAGR 4Y +53.6%
Sales Q/Q +33.6%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.